ONCOTARGET: TAKING THE WORLD TOWARDS A DISEASE FREE GENERATION

Oncotarget is a medical journal that is published weekly online to break the barriers that exist in Oncology in the world. The peer-reviewed publication provides information about research on Oncology. However, all issues may be printed on special demand. Oncotarget is a powerhouse of all cancers as it covers practically all aspects of the disease. Some of the issues it covers include; the open-access international journal delves deeply into the causes of all types of cancers.The journal also includes the current and advanced treatment options for the various types of cancers. It also talks about how the improvement of the management of oncology patients can be done according to their treatment protocols.

The medical journal also covers the effect of the programs that manage cancer and emerging protocols and therapeutic agents. It also looks into the patient’s point of view when it comes to satisfaction, their way of life, and perseverance. The journal also seeks to prove the evidence of both emerging and current therapies. It will also look into how they are utilized and accepted by the patients and the general medic population. Nonetheless, the weekly health publications’ main objective is to penetrate the Oncology scientific research frontier by availing and spreading all the current information rapidly. It also seeks to avail the latest discoveries on Oncology by dividing them equally, to ensure that the effect of Oncology research is felt equally and to allow different aspects of clinical and basic science to inter-relate and produce better results in treating Oncology patients.

Therefore, the online medical publication is a link for various professionals in the biomedical science field to interrelate and produce better results that will be beneficial to the patient.Oncotarget’s Editor in Chief is Dr, Faris Farassati. However, the magazine is led by renowned scientists, and it assists all researchers to contribute towards a disease-free world. The journal is indexed online, and it is a member of Committee on Publication Ethics (COPE). The journal also subscribes to the principles of this body. In addition to this, the journal also has a section that covers other medical fields which may be related to Oncology. This includes cell death and Circadian rhythm, pathology, microbiology, neuroscience, immunology, neurotarget and autophagy among others.

What Eric Lefkofsky Di in Answer to His Wife’s Cancer

Friends often designate Eric Lefkofsky, a “serial entrepreneur.” However, with the multiple charitable interests that he and his wife Liz donate time and money to, the correct designation should be “serial philanthropist.” Instead of sitting on the sidelines with the money they have generated, this couple invests considerable funds and ample time into a series of charities in the fields of education, health, human rights, arts and culture, and the development of new technologies for the advancement of those other interests in which they were involved for more info: http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life click here.

As an entrepreneur, Eric started as a carpet salesman in his college years. Eric did not rest after school. He immediately threw himself into business, sometimes failing, sometimes succeeding, but always learning. Today, Eric Lefkofsky works adjunct professor at the University of Chicago Booth School of Business, is a Co-Founder of such businesses as Groupon, Zest Health, Echo Global Logistics, and Inner Workings. He is a Founding Partner in Lightbank, and Co-Founder and CEO pf Tempus. With boundless energy and a wealth of experience in the business community, Eric’s record speaks for itself.

Currently, Eric is concentrating on the creation of databases to facilitate the understanding of how cancer treatments work. Eric, with the force of Liz behind him, helped to found Tempus for the specific purpose of creating an overlay system atop the already existing Medical Record System to facilitate interaction and discovery of how cancer treatments successfully work for one set of people living with cancer but not for others.

Eric came up with the idea following Liz’s breast cancer diagnosis. The couple was stunned to learn while sitting together in the oncologist’s office discussing treatment options, thatoncologists had no access to information to answer questions about why some cancer patients reacted well to treatments while others did not.

The answer to the conundrum, at least for Eric, was to create a system which would allow oncologists to find information regarding cancer treatment success or failures for patients similar to the patient currently sitting in their office. Thus, the concept of the overlay system that would sift through medical records, find similar cases, and analyze the correct treatment bore the fruit of Tempus.

Clay Siegall: Fighting Cancer One Patient At A Time

When Dr. Clay Siegall founded his company, Seattle Genetics, in 1998, he has acquired over twenty years experience in cancer research. This experience has set the goals of Seattle Genetics to give Doctors better cancer treatment tools, and to help treat cancer patients with better therapies for everyday living.

These goals are personal for Clay as he watched his own father pass away from suffering with cancer for years. As a young man, this experience has had a profound impact on Clay, so he dedicated himself to finding a more advanced way of treating cancer.

Under Clay Siegall‘s leadership, he has raised 1.2 billion to date to fund cancer research and treatment. One cancer treatment that has been generated is ADCETRIS. This medicine is an ADC (antibody drug conjugate). ADC target only cancer cells, and will leave healthy cells intact. This is significant for cancer patients as it will decrease healing time and lessen side effects often seen in traditional cancer treatments.

ADCETRIS has currently been approved in over 64 countries as a viable treatment option and Seattle Genetics has entered into partnerships with other pharmaceutical companies sharing the ADC technology. Right now there are over 20 ADCs been produced thanks to this partnership.

Dr. Siegall entered the workforce years ago, first working for National Cancer Institute, National Institutes of Health as a researcher, and for Bristol-Myers Squibb Pharmaceutical Research Institute before building his own business.

Dr. Siegall is passionate about cancer treatment and the overall medical treatment of cancer patients. That is why Clay also serves on the boards of Alder BioPharmaceuticals and Ultragenyx Pharmaceutical. And on the Board of Directors for Washington Roundtable. Dr. Siegall has received his Bachelors of Science in Zoology from the University of Maryland, and his PhD in Genetics from George Washington University.